Gout, despite being one of the most well-known and recognizable rheumatic diseases, still has large populations of people struggling with its management, as they do not receive urate-lowering treatment, even when they qualify. Of those who receive this treatment, only a small percentage reach their target urate goal. To shed some light on this, we’ve invited Dr. Nicola Dalbeth, a Specialist Rheumatologist, who leads research on the mechanisms, impact and treatment of gout. Dr. Dalbeth is also a principal investigator of trials for novel therapeutic agents and treatment strategies in gout and in 2020, was also a member of the core oversight committee for the ACR Gout Management Guidelines. We discuss treatment efficacy, the disparities, myths and barriers to them, diagnosis, and strategies regarding management of gout.

51. Gout

ACR on Air